Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rangering i aksjer #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Aksjekurs
$59.43
Markedsverdi
$121.03B
Endring (1 dag)
0.83%
Endring (1 år)
0.90%
Land
US
Handel Bristol-Myers Squibb Company (BMY)

Kategori

Inntekter for Bristol-Myers Squibb Company (BMY)
Inntekter i Dec 2025 TTM: $9.33B
Ifølge Bristol-Myers Squibb Company sine nyeste økonomiske rapporter er selskapets nåværende resultat $9.33B. I 2024 hadde selskapet et resultat på $-8.38B, en nedgang sammenlignet med resultatet i 2023, som var $8.44B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Bristol-Myers Squibb Company fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $9.33B 0.00%
2025 $9.33B -211.33%
2024 $-8.38B -199.28%
2023 $8.44B 9.43%
2022 $7.71B -4.75%
2021 $8.10B -217.86%
2020 $-6.87B -238.11%
2019 $4.98B -16.64%
2018 $5.97B 16.31%
2017 $5.13B -13.25%
2016 $5.92B 184.79%
2015 $2.08B -12.77%
2014 $2.38B -17.64%
2013 $2.89B 23.55%
2012 $2.34B -66.48%
2011 $6.98B 14.99%
2010 $6.07B 8.37%
2009 $5.60B 17.29%
2008 $4.78B 35.14%
2007 $3.53B 47.25%
2006 $2.40B -44.24%
2005 $4.30B -2.58%
2004 $4.42B -5.60%
2003 $4.68B 69.50%
2002 $2.76B 24.48%
2001 $2.22B -59.51%
2000 $5.48B 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$25.73B 175.84%
US
$12.40B 32.95%
GB
$32.58B 249.28%
US
$6.60B -29.28%
US
$16.35B 75.30%
CH